WO2002016409A2 - Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies - Google Patents
Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies Download PDFInfo
- Publication number
- WO2002016409A2 WO2002016409A2 PCT/EP2001/009576 EP0109576W WO0216409A2 WO 2002016409 A2 WO2002016409 A2 WO 2002016409A2 EP 0109576 W EP0109576 W EP 0109576W WO 0216409 A2 WO0216409 A2 WO 0216409A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- carrier
- cyclised
- peptides
- ige
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 182
- 229960005486 vaccine Drugs 0.000 title claims abstract description 40
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 16
- 230000007815 allergy Effects 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 59
- 230000008569 process Effects 0.000 claims abstract description 37
- 230000002163 immunogen Effects 0.000 claims abstract description 23
- 208000026935 allergic disease Diseases 0.000 claims abstract description 14
- 150000003568 thioethers Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 20
- 229940098773 bovine serum albumin Drugs 0.000 claims description 20
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 18
- 101710188053 Protein D Proteins 0.000 claims description 18
- 101710132893 Resolvase Proteins 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 17
- 239000000969 carrier Substances 0.000 claims description 17
- 150000003573 thiols Chemical group 0.000 claims description 14
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000001268 conjugating effect Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 3
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical group N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 74
- 230000021615 conjugation Effects 0.000 abstract description 16
- 239000000543 intermediate Substances 0.000 abstract description 12
- 102000001189 Cyclic Peptides Human genes 0.000 abstract description 9
- 108010069514 Cyclic Peptides Proteins 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000001311 chemical methods and process Methods 0.000 abstract description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 229960001340 histamine Drugs 0.000 description 25
- 239000000562 conjugate Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical class O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 238000007792 addition Methods 0.000 description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 10
- 239000013566 allergen Substances 0.000 description 10
- 210000003651 basophil Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 102000009438 IgE Receptors Human genes 0.000 description 7
- 108010073816 IgE Receptors Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 108091005573 modified proteins Proteins 0.000 description 7
- 102000035118 modified proteins Human genes 0.000 description 7
- 125000005413 thiopyridyl group Chemical group 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- -1 bromoacetyl group Chemical group 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 108091005601 modified peptides Proteins 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000011537 Coomassie blue staining Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 125000002228 disulfide group Chemical group 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- MISJXUDJCSZFAH-UHFFFAOYSA-N 1-sulfanylpyridin-2-one Chemical compound SN1C=CC=CC1=O MISJXUDJCSZFAH-UHFFFAOYSA-N 0.000 description 2
- NCPQROHLJFARLL-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound OC(=O)CCCN1C(=O)C=CC1=O NCPQROHLJFARLL-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SUMXKTYOTRXZDA-UHFFFAOYSA-N 1-hydroxypyrrolidine-2,5-dione;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.ON1C(=O)CCC1=O SUMXKTYOTRXZDA-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000380131 Ammophila arenaria Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101100268521 Bos taurus SERPINA1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101001015673 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Glycerophosphodiester phosphodiesterase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100522111 Oryza sativa subsp. japonica PHT1-11 gene Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to a novel chemical process for the covalent conjugation of disulphide bridge cyclised peptides to immunogenic carrier molecules by thio-ether linkages to form vaccine immunogens.
- the novel chemistry involves reacting a thiolated carrier with a cyclic peptide containing a disulphide bridge, which cyclic peptide (herein a disulphide bridge cyclised peptide) has attached to it, usually via a linker, a reactive group capable of forming thio-ether bonds with the carrier.
- the invention further relates to activated peptide intermediates of the process, medicaments produced by the process, pharmaceutical compositions containing the medicaments, and the use of the pharmaceutical compositions in medicine.
- the process of the present invention is particularly useful for the preparation of highly pure immunogens for vaccines, comprising disulphide bridge cyclised peptides.
- novel immunogens are provided, based on peptides derived from the sequence of human IgE, which are useful in the immunotherapy of allergy. Accordingly, the invention relates also to a process for conjugation of IgE disulphide bridge cyclised peptides to carriers, immunogens produced by the process and vaccines and pharmaceutical compositions comprising them and their use in the treatment of allergy.
- Immunogens comprising short peptides are becoming increasingly common in the field of vaccine prophylaxis or therapy. In many disease states it is often possible, and desirable, to design vaccines comprising a short peptide rather than a large protein.
- Peptides which may be used as immunogens may be the full length native protein, for example human peptidic hormones, or may be fragments of a larger antigen derived from a given pathogen, or from a large self-protein.
- short peptides of IgE may be used for prophylaxis of allergy, whereas the use of IgE itself as the immunogen may induce anaphylactic shock.
- peptides per se are poor immunogens.
- sequences of the peptides chosen are such that they include a B-cell epitope to provide a target for the generation of anti-peptide antibody responses, but because of their limited size rarely encompass sufficient T-cell epitopes in order to provide the necessary cytokine help in the induction of strong immune responses following priming and boosting applications of the vaccine.
- the carrier proteins contain a large number of peptidic T-cell epitopes which are capable of being loaded into MHC molecules, thereby providing bystander T-cell help, and/or alternatively the use of strong adjuvants in the vaccine formulation.
- highly immunogenic carriers which are currently commonly used for the production of peptide immunogens include the Diptheria and Tetanus toxoids (DT and TT respectively), Keyhole Limpet Haemocyanin (KLH), and the purified protein derivative of Tuberculin (PPD).
- Peptides used in a particular vaccine immunogen are often chosen such that they generate an antibody response to the location site of that peptide in the context of the full length native protein.
- the peptide in the immunogen must assume substantially the same shape as it would exist if it was confined by the flanking regions of the full length native protein.
- conjugating a linear peptide sequence, by conventional chemistry, to a carrier protein rarely achieves this goal.
- the cyclised peptide thus formed is commonly conjugated to a protein carrier to form an immunogen by one of several chemistry methods.
- chemistries include conjugation of amino groups between the peptide and carrier by amino reactive agents such as glutaraldehyde or formaldehyde; or condensing carboxyl groups and amino groups with carbodiimide reagents or alternatively by converting n-terminal ⁇ -hydroxy groups to aldehydes by an oxidation reaction and conjugating this group to an amino or oxamino moiety.
- each of these chemistries has disadvantages, including a need for relatively harsh oxidative reaction conditions, poor controllability at industrial levels, formation of polymers, or not being suitable for peptides that contain specific internal amino acids (especially: Lysine, Aspartic acid, Glutamic acid, Tryptophan, Tyrosine or Serine) that could also interfere with the chemistry in an inappropriate manner.
- specific internal amino acids especially: Lysine, Aspartic acid, Glutamic acid, Tryptophan, Tyrosine or Serine
- thio-ether linkage to conjugate peptides to protein carriers.
- the most common method to achieve this conjugation is to add a moiety with a terminal thiol group onto the peptide, most commonly by adding a cysteine, and then to react the reactive thiol group with a maleimide-derivatised protein carrier (Friede et al, 1994, Naccine, 12, 791- 797), for a schematic summary see FIG 1.
- each of the reassortant intermediates is equally reactive with the reactive carrier protein, and as such they will all conjugate to the carrier.
- the purity of the desired product is decreased, and use of this mixture of immunogens may result in immune responses that may not, or only weakly, cross react with the epitope on the full native protein that the peptide was intended to mimic.
- several authors have replaced the disulphide bond stabilised cyclic peptides, by thio-ether bonds.
- the present invention overcomes the problems of forming a thio-ether linkage between a disulphide cyclised peptide and a carrier by providing a chemistry that does not use a terminal thiol containing group on the cyclised peptide, but instead uses another reactive group on the peptide, which may then be reacted with a thiolated carrier protein to form a thio-ether bond.
- a process for the manufacture of a vaccine immunogen comprising conjugating a disulphide bridge cyclised peptide to an immunogenic carrier comprising, (a) adding to a disulphide cyclised peptide a moiety comprising a reactive group which is capable of forming thio-ether linkages with thiol bearing carriers, and (b) reacting the activated cyclised peptide thus formed with a thiol bearing immunogenic carrier.
- the process of the present invention overcomes the problems of internal and external disulphide rearrangement, and in addition provides conjugated products wherein the disulphide cyclised peptides are in the desired conformation.
- a peptide is synthesised containing two cysteine residues which are allowed to form a disulphide bridge, followed by the addition of the reactive group.
- the activated peptide, thus obtained, is then reacted with the thiol bearing carrier.
- the reactive groups that are suitable for use in the present invention include any group which is capable forming thio-ether linkages with thiolated carriers.
- preferred reactive groups may be selected from active imides, especially maleimides, haloalkyl groups such as iodoalkyl or bromoalkyl groups.
- the bromoalkyl group is a bromoacetyl group.
- a preferred process for conjugating a disulphide bridge cyclised peptide to a carrier comprises, (a) adding to a disulphide cyclised peptide a moiety comprising a maleimide group, and (b) reacting the activated cyclised peptide thus formed with a thiol bearing carrier.
- the product of this process (A conjugate suitable for use in a vaccine) forms an aspect of the present invention, and has the formula (I):
- Carrier is a carrier molecule
- X is either a linker or a bond
- Y is either a linker or a bond
- P is a disulphide bridge cyclised peptide.
- X is a bond
- Y is a linker
- P is a disulphide bridge cyclised peptide.
- X is a bond
- Y is a linker
- the disulphide bridge cyclised peptide is linked directly to the nitrogen atom ⁇ .
- a "linker” refers to a suitable linker group.
- When X is a linker group an example is the group - ⁇ HCO(CH 2 ) 2 -.
- Y is a linker group
- an example is -(CH 2 ) 3 - CONH-.
- Forming an aspect of the invention is the intermediate to the process of the present invention, which is a disulphide cyclised peptide which bears a reactive group which is capable forming thio-ether linkages with thiolated carriers.
- said intermediate comprises a disulphide bridge cyclised peptide linked to an active imide group, in particular a maleimide group.
- the high purity of the final conjugated product derives from the fact that any internal or external rearrangement that occurs between the disulphide bridge and the thio-ether reactive group is irreversible, and consequently these reassortant intermediates are not reactive with the thiolated carrier protein. Only the activated peptide intermediates that have the disulphide bridge at the desired location (i.e. between the cysteines present in the peptide) with the free reactive group participate in the conjugation reaction with the thiolated carrier, thereby forming a conjugate of extremely high purity which contains cyclised peptides of the desired conformation.
- Preferred maleimide derivatisation reagents are gamma-maleimidobutyric acid N- hydroxysuccinimide ester (GMBS, Molecular Formula: C 12 H 12 N 2 O 6) Fujiwara, K., et al, J. Immunol. Meth., 45, 195-203 (1981), Tanimori, H., et al, J. Pharmacobiodyn., 4, 812-819 (1981); H. Tanimori, et al., J. Immunol. Methods 62, 123 (1983); M.D. Partis, et al, J. Prot. Chem. 2, 263 (1983); L. Moroder, et al., Biopolymers 22, 481 (1983); S.
- GMBS gamma-maleimidobutyric acid N- hydroxysuccinimide ester
- the process, intermediates and products of the present invention are preferably used in the manufacture of immunogens for use in vaccines.
- the peptides for conjugation may be selected from any antigen against which is desired to create an immune response.
- the peptide may be derived from a pathogen, such as a virus, bacterium, parasite such as a worm etc. Equally the peptide may be selected from a self protein, for example in the vaccine therapy of cancer or allergy.
- allergen specific IgE In an allergic response, the symptoms commonly associated with allergy are brought about by the release of allergic mediators, such as histamine, from immune cells into the surrounding tissues and vascular structures. Histamine is normally stored in mast cells and basophils, until such time as the release is triggered by interaction with allergen specific IgE.
- IgE The role of IgE in the mediation of allergic responses, such as asthma, food allergies, atopic dermatitis, type-I hypersensitivity and allergic rhinitis, is well known.
- B-cells On encountering an antigen, such as pollen or dust mite allergens, B-cells commence the synthesis of allergen specific IgE. The allergen specific IgE then binds to the Fc ⁇ RI receptor (the high affinity IgE receptor) on basophils and mast cells.
- IgE like all immunoglobulins, comprises two heavy and two light chains.
- the ⁇ heavy chain consists of five domains: one variable domain (VH) and four constant domains (C ⁇ l to C ⁇ 4).
- VH variable domain
- C ⁇ l to C ⁇ 4 constant domains
- IgE domains consists of a squashed barrel of seven anti- parallel strands of extended ( ⁇ -) polypeptide segments, labelled a to f, grouped into two ⁇ - sheets.
- Four ⁇ -strands (a,b,d & e) form one sheet that is stacked against the second sheet of three strands (c,f& g) (see FIG 8).
- each ⁇ -sheet is maintained by lateral packing of amino acid residue side-chains from neighbouring anti-parallel strands within each sheet (and is further stabilised by main-chain hydrogen-bonding between these strands).
- Loops of residues, forming non-extended (non- ⁇ -) conformations connect the anti-parallel ⁇ -strands, either within a sheet or between the opposing sheets.
- the connection from strand a to strand b is labelled as the A-B loop, and so on.
- the A-B and d-e loops belong topologically to the four- stranded sheet, and loop/-g to the three-stranded sheet.
- the interface between the pair of opposing sheets provides the hydrophobic interior of the globular domain. This water- inaccessible, mainly hydrophobic core results from the close packing of residue side-chains that face each other from opposing ⁇ -sheets.
- WO 97/31948 describes an example of this type of work, and further describes IgE peptides from the C ⁇ 3 and C ⁇ 4 domains conjugated to carrier molecules for active vaccination purposes. These immunogens may be used in vaccination studies and are said to be capable of generating antibodies which subsequently inhibit histamine release in vivo .
- a monoclonal antibody (BSW17) was described which was said to be capable of binding to IgE peptides contained within the C ⁇ 3 domain which are useful for active vaccination purposes.
- EP 0 477 231 Bl describes immunogens derived from the C ⁇ 4 domain of IgE
- peptide intermediates, immunogens and vaccines comprise a peptide selected from human IgE.
- disulphide bridge cyclised peptides used in the present invention are designed from the group of peptides listed in table 1. The peptides in table 1, reflect a specific area of the IgE molecule against which it is desired to generate an immune response.
- peptides therefore, constitute a starting point from which a cyclised peptide may be designed, and accordingly they either do not contain a cysteine residue, or contain a single cysteine, or contain two cysteines which may not form a disulphide bridge.
- Suitable peptides for use in the process or immunogens of the present mvention may be designed by the addition of at least one cysteine residue to the following peptides:
- ADGAECFINKQRADLELCPGEAAEA 212 ADGAGCFINKQMADSELCPAAAAEA 213 ADGAGCFLNRQMADPELCPREAAEA 214
- Immunogens produced by the process of the present invention which may incorporate the modified peptides of table 1, or the cyclic peptides of table 2, form a preferred aspect of the present mvention.
- Mimotopes which have the same characteristics as these peptides, and immunogens comprising such mimotopes which generate an immune response which cross- react with the IgE epitope in the context of the IgE molecule, also form part of the present invention.
- the meaning of mimotope is defined as an entity which is sufficiently similar to the native IgE peptides listed in tables 1 or 2, so as to be capable of being recognised by antibodies which recognise the native IgE peptide; (Gheysen, H.M., et al., 1986, Synthetic peptides as antigens.
- the preferred peptides to be used in the process or immunogens of the present invention mimic the surface exposed regions of the IgE structure, however, within those regions the dominant aspect is thought by the present inventors to be those regions within the surface exposed area which correlate to a loop structure.
- the structure of the domains of IgE are described in "Introduction to protein Structure” (page 304, 2 nd Edition, Branden and Tooze, Garland Publishing, New York, ISBN 0 8153 2305-0) and take the form a ⁇ -barrel made up of two opposing anti-parallel ⁇ -sheets (see FIG. 8).
- the immunogens may comprise a disulphide bridge cyclised peptide which is a sequence derived from a loop of the IgE - domains.
- Preferred examples of this are the A-B loop of C ⁇ 3, the A-B loop of C ⁇ 4, the C-D loop of C ⁇ 3, the C-D loop of C ⁇ 4, the A-B loop of C ⁇ 2 and the C-D loop of C ⁇ 2.
- Peptide mimotopes of the above-identified IgE epitopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids.
- the peptides of the present invention may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine to the IgE epitope.
- peptides conjugated to a protein carrier may include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein.
- the peptides may be altered to have an N-terminal cysteine and a C- terminal hydrophobic amidated tail.
- the addition or substitution of a D- stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.
- modified peptides, or mimotopes could be a wholly or partly non-peptide mimotope wherein the constituent residues are not necessarily confined to the 20 naturally occurring amino acids.
- these may be cyclised by techniques known in the art to constrain the peptide into a conformation that closely resembles its shape when the peptide sequence is in the context of the whole IgE molecule.
- a preferred method of cyclising a peptide comprises the addition of a pair of cysteine residues to allow the formation of a disulphide bridge.
- mimotopes or immunogens of the present invention may be larger than the above-identified epitopes, and as such may comprise the sequences disclosed herein. Accordingly, the mimotopes of the present invention may consist of addition of N and/or C terminal extensions of a number of other natural residues at one or both ends.
- the peptide mimotopes may also be retro sequences of the natural IgE sequences, in that the sequence orientation is reversed; or alternatively the sequences may be entirely or at least in part comprised of D-stereo isomer amino acids (inverso sequences).
- the peptide sequences may be retro-inverso in character, in that the sequence orientation is reversed and the amino acids are ofthe D-stereoisomer form.
- retro or retro-inverso peptides have the advantage of being non-self, and as such may overcome problems of self- tolerance in the immune system (for example PI 4c).
- peptide mimotopes may be identified using antibodies which are capable themselves of binding to the IgE epitopes ofthe present invention using techniques such as phage display technology (EP 0 552 267 Bl). This technique, generates a large number of peptide sequences which mimic the structure ofthe native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native IgE peptide.
- This approach may have significant advantages by allowing the possibility of identifying a peptide with enhanced immunogenic properties (such as higher affinity binding characteristics to the IgE receptors or anti-IgE antibodies, or being capable of inducing polyclonal immune response which binds to IgE with higher affinity), or may overcome any potential self-antigen tolerance problems which may be associated with the use ofthe native peptide sequence. Additionally this technique allows the identification of a recognition pattern for each native-peptide in terms of its shared chemical properties amongst recognised mimotope sequences.
- peptide mimotopes may be generated with the objective of increasing the immunogenicity ofthe peptide by increasing its affinity to the anti-IgE peptide polyclonal antibody, the effect of which may be measured by techniques known in the art such as (Biocore experiments) .
- the peptide sequence may be electively changed following the general rules:
- each amino acid residue can be replaced by the amino acid that most closely resembles that amino acid.
- A may be substituted by V, L or I, as described in the following table 3.
- the present invention therefore, provides a process for the manufacture of a vaccine and novel immunogens comprising disulphide bridge cyclised peptides conjugated by the process ofthe present invention, and the use ofthe immunogens in the manufacture of pharmaceutical compositions for the prophylaxis or therapy of disease.
- the process and the immunogens ofthe present invention are used in vaccines for the immunoprophylaxis or therapy of allergies.
- the peptides used in the process of present invention will be of a small size. Peptides, therefore, should be less than 100 amino acids in length, preferably shorter than 75 amino acids, more preferably less than 50 amino acids, and most preferable within the range of 4 to 25 amino acids long.
- the most preferred peptides for use in the processes and conjugates ofthe present invention are SEQ ID NO.s 99, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, and 328.
- the types of immunogenic carriers used in the immunogens ofthe present invention will be readily known to the man skilled in the art.
- the preferred function ofthe carrier is to provide cytokine help in order to help induce an immune response against the IgE peptide.
- a non-exhaustive list of carriers which may be used in the present invention include: Keyhole limpet Haemocyanin (KLH), serum albumins such as bovine serum albumin (BSA), inactivated bacterial toxins such as tetanus or diptheria toxins (TT and DT), or recombinant fragments thereof (for example, Domain 1 of Fragment C of TT, or the translocation domain of DT), or the purified protein derivative of tuberculin (PPD).
- KLH Keyhole limpet Haemocyanin
- BSA bovine serum albumin
- TT and DT inactivated bacterial toxins
- TT and DT diptheria toxins
- PPD purified protein derivative of tuberculin
- the process may be used to conjugate the cyclic peptides directly to liposome carriers, which may additionally comprise carriers capable of providing T-cell help.
- the ratio of peptides to carrier is in the order of 1:1 to 20:1, and preferably each carrier should carry between 3-15 peptides.
- a preferred carrier is Protein D from Haemophilus influenzae (EP 0 594 610 Bl). Protein D is an IgD-binding protein from Haemophilus influenzae and has been patented by Forsgren (WO 91/18926, granted EP 0 594 610 Bl).
- Protein D l/3 rd comprising the N- terminal 100-110 amino acids of protein D (GB 9717953.5).
- Peptides can be readily prepared using the 'Fmoc' procedure, utilising either polyamide or polyethyleneglycol-polystyrene (PEG-PS) supports in a fully automated apparatus, through techniques well known in the art (techniques and procedures for solid phase synthesis are described in 'Solid Phase Peptide Synthesis: A Practical Approach' by E. Atherton and R.C. Sheppard, published by IRL at Oxford University Press (1989)) followed by acid mediated cleavage to leave the linear, deprotected, modified peptide.
- This peptide can be readily oxidised and purified to yield the disulphide-bridge modified peptide, using methodology outlined in 'Methods in Molecular Biology, Vol.
- the peptides may be produced by recombinant methods, including expressing nucleic acid molecules encoding the mimotopes in a bacterial or mammalian cell line, followed by purification ofthe expressed mimotope.
- Techniques for recombinant expression of peptides and proteins are known in the art, and are described in Maniatis, T., Fritsch, E.F. and Sambrook et al, Molecular cloning, a laboratory manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
- each vaccine dose is selected as an amount which induces an immunoprotective response without significant adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 1-500 ⁇ g, more preferably 1-100 ⁇ g, of which 1 to 50 ⁇ g is the most preferable range. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
- Vaccines ofthe present invention may advantageously also include an adjuvant.
- Suitable adjuvants for vaccines ofthe present invention comprise those adjuvants that are capable of enhancing the antibody responses against the immunogen.
- Adjuvants are well known in the art (Vaccine Design - The Subunit and Adjuvant Approach, 1995, Pharmaceutical Biotechnology, Volume 6, Eds. Powell, M.F., and Newman, M.J., Plenum Press, New York and London, ISBN 0-306-44867-X).
- Preferred adjuvants for use with immunogens ofthe present invention include aluminium or calcium salts (for example hydroxide or phosphate salts).
- Preferred adjuvants for use with immunogens ofthe present invention include: aluminium or calcium salts (hydroxide or phosphate), oil in water emulsions (WO 95/17210, EP 0 399 843), or particulate carriers such as Hposomes (WO 96/33739).
- Immunologically active saponin fractions e.g. Quil A
- QS21 an HPLC purified fraction derivative of Quil A
- the method of its production is disclosed in US Patent No.5,057,540.
- 3 De-O-acylated monophosphoryl lipid A is a well known adjuvant manufactured by Ribi Immunochem, Montana. It can be prepared by the methods taught in GB 2122204B.
- a preferred form of 3 De-O-acylated monophosphoryl lipid A is in the form of an emulsion having a small particle size less than 0.2 ⁇ m in diameter (EP 0 689 454 Bl).
- Adjuvants also include, but are not limited to, muramyl dipeptide and saponins such as Quil A, bacterial lipopolysaccharides such as 3D-MPL (3-O-deacylated monophosphoryl lipid A), or TDM.
- the protein can be encapsulated within microparticles such as hposomes, or in non-particulate suspensions of polyoxyethylene ether (UK Patent Application No. 9807805.8).
- Particularly preferred adjuvants are combinations of 3D-MPL and QS21 (EP 0 671 948 Bl), oil in water emulsions comprising 3D-MPL and QS21 (WO 95/17210, PCT/EP98/05714), 3D-MPL formulated with other carriers (EP 0 689 454 Bl), or QS21 formulated in cholesterol containing Hposomes (WO 96/33739), or immunostimulatory oligonucleotides (WO 96/02555).
- Alternative adjuvants include those described in WO 99/52549.
- the vaccines ofthe present invention will be generally administered for both priming and boosting doses.
- Boosting doses may consist ofthe peptide in the absence ofthe original carrier molecule.
- booster constructs may comprise an alternative carrier or may be in the absence of any carrier.
- an immunogen or vaccine as herein described for use in medicine.
- the vaccine preparation ofthe present invention may be used to protect or treat a mammal susceptible to, or suffering from allergies, by means of administering said vaccine via systemic or mucosal route.
- administrations may include injection via the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or via mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.
- a preferred route of administration is via the transdermal route, for example by skin patches. Accordingly, there is provided a method for the treatment of allergy, comprising the administration of a peptide, immunogen, or ligand ofthe present invention to a patient who is suffering from or is susceptible to allergy.
- Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Conjugation of proteins to macromolecules is disclosed by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.
- Example 1 Conjugation of disulphide cyclised peptide to a carrier, by conjugating a maleimide activated peptide to thiolated Protein D or BSA as a carrier.
- a maleimide derivatised cyclic peptide is reacted with a thiol bearing carrier.
- the thiol group being generated on either Protein D (PD) or BSA as the carrier by reduction ofthe SPDP derivative ofthe carrier.
- N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) is a heterobifunctional cross-linking agent which under mild conditions, reacts by its NHS-ester group with amino groups of he protein (Fig; 3) (Hermanson G.T. Bioconjugate Techniques, 1996). NHS-ester crossliriking reactions are most commonly performed in phosphate, bicarbonate/carbonate and borate buffers.
- a SPDP modified protein with DTT Dithiothreitol, or another disulfide-reducing agent
- DTT Dithiothreitol, or another disulfide-reducing agent
- Fig 3 A The reaction is generally performed with 25 mM DTT at pH 4.5 to avoid the reduction ofthe protein's S-S bonds.
- the DTT reduction may be performed at pH 7-9.
- the reaction between a maleimide group added on the peptide and the sulfhydryl groups present on the carrier produces the immunogen ofthe present invention (Fig. 3B).
- the maleimide-activated peptide was obtained by reaction between the peptide (P) and a heterobifunctionnal cross-linking reagent like GMBS (gamma-maleimidobutyric acid N-hydroxysuccinimide ester).
- GMBS gamma-maleimidobutyric acid N-hydroxysuccinimide ester
- BSA (Pierce) is dissolved at a concentration of 10 mg/ml in 50 mM sodium phosphate, 0.15
- SPDP was dissolved at a concentration of 6.2 mg/ml in DMSO (makes a 20 mM stock solution). A sufficient quantity ofthe stock solution of SPDP was then added to the protein to be modified (for BSA, a 15 fold molar excess of SPDP over protein, and for PD, a 25 fold molar excess). After one hour at room temperature, the modified protein was purified from reaction by products by dialysis against 50 mM sodium phosphate, 10 mM EDTA pH 6.8 or by gel filtration.
- the sample is applied on a desalting column (Sephadex G25) equilibrated with phosphate buffer pH 6.8 (or 100 mM sodium acetate, 0.15 M NaCl, 1 mM EDTA pH 4.5 if S-S containing proteins are to be reduced in the next step). Fractions of 1 ml are collected and monitored by adsorbance at 280 nm. Fractions containing SPDP modified protein are pooled. The number of thiopyridyl groups introduced in BSA is estimated spectrophotometrically: transfer 200 ⁇ l of modified BSA in a spectrophotometer cuvette and add 200 ⁇ l of 50 mM mercaptoethanol in 100 mM phosphate buffer, pH 7. Measure absorbance at 343 n before and after addition of mercaptoethanol. Evaluate the quantity of thiopyridone liberated using A ⁇ ⁇ ⁇ OOO M-W.
- DTT was added to a final concentration of 1-10 mM. Incubate for 2 h at room temperature. For removal of excess of DTT, gel filtration using Sephadex G-25 was used. To maintain the stability ofthe exposed sulfhydryl groups, 10 mM EDTA was included in the chromatography buffer (100 mM sodium phosphate pH 6.8). The presence of oxidized DTT can be monitored during elution by measuring the absorbance at 280 nm.
- maleimide activated peptide (about 22 fold molar excess of maleimide activated peptide over the protein) was added to the SPDP modified protein and was agitated during 1 hr at room temperature followed by three dialysis against 100 mM Na phosphate pH 6.8. After filtration through 0.2 ⁇ m pore size (millipore filter), protein content was estimated by Lowry.
- a maximum of 8 to 10 thiopyridyl groups can be added on BSA.
- a higher thiopyridyl number can be obtained if a 20 fold molar excess of SPDP over BSA was used (Fig. 6). However, a slight clouding was then observed during the reaction resulting in a lower yield of SPDP modified BSA.
- EDGQVMDVD (SEQ ID NO. 1) pl5a: GGCLEDGQVMDVDC (SEQ ID NO. 324) pi 5b: Ac-CLEDGQVMDCGSK-NH 2 (SEQ ID NO. 325) pl5c: Ac-CLEDGQVMDVDLCGSK-NH 2 (SEQ ID NO. 326) pl5d: Ac-CLEDGQVMDVDLCPREAAEGDK-NH 2 (SEQ ID NO. 327) pl5e: Ac-CLEDGQVMDVDLCGGSSGGK-NH 2 (SEQ ID NO. 328)
- the resulting conjugates were soluble and were characterized by SDS-PAGE (coomassie blue-staining and western blot) (Fig. 7B, lane 7, Fig. 8 and Fig.9).
- Disulfide exchange reactions involve attack ofthe thiol at the disulfide, breaking the S-S bond, with subsequent formation of a new mixed disulfide constituting a portion ofthe original disulfide compound. If the thiol is present in excess, the mixed disulfide can go on to form a symmetrical disulfide consisting entirely ofthe thiol reducing agent. If the thiol is not present in large excess, the mixed disulfide product is the end result.
- a positive control was included resulting from the reaction between SPDP-modified BSA and pi 4a peptide (AcAPEWPGSRDKRTLAGGC) in which disulfide interchange occurs (Fig. 3 A).
- the resulting conjugate was purified by dialysis or by gel filtration.
- the combination of two chemistries was used to conjugate constrained peptides to a carrier. Soluble conjugates with 6 to 8 peptides on the carrier were obtained and were characterized by SDS-PAGE with antibodies against pi 4. The resulting conjugates were principally obtained by the reaction between the GMBS activated peptide and BSA-SH and not by disulfide interchange as confirmed by Western-blot. These results demonstrate that these chemistries can be used to conjugate constrained peptides to a carrier.
- the maleimide was added to the peptide via reaction of maleimide-N- hydroxysuccinimide ester reagents with a lysine side-chain or with a N-terminal amino group.
- the maleimide group can be readily conceived: notably for peptides containing a lysine within the epitope, the maleimide can be added during peptide synthesis prior to final deprotection ofthe side-chains and cleavage ofthe peptide.
- Example 2 Immune response induced by different disulphide bridged peptide-BSA conjugates.
- mice per group were immunised intramuscularly (IM) on days 0, 14 and 28 with 25 ⁇ g of conjugate mixed with AS2 adjuvant (oil/water emulsion, 3D-MPL, QS21).
- AS2 adjuvant oil/water emulsion, 3D-MPL, QS21.
- the serologic response for the P 14 peptides was analysed by ELISA on days 28 and 42 (14 post III). The results are shown below in Table 4.
- the PI 5 peptide conjugates produced in Example 1 were also used to immunise 10 mice per group,intramuscularly (IM) on days 0, 14 and 28 with 25 ⁇ g of conjugate mixed with AS2 adjuvant (oil/water emulsion, 3D-MPL, QS21).
- AS2 adjuvant oil/water emulsion, 3D-MPL, QS21.
- Anti peptide and anti-IgE antibody responses are shown in Table 5 (14 days post III). Very homogenous responses were obtained with all cyclic PI 5 peptides.
- Anti-IgE antibody responses were assayed by comparison with a monoclonal antibody, mAbl 1, which is known to recognise the PI 5 target site (c-d loop of C ⁇ 2) and inhibit histamine release in the Human Basophil Assay, the levels of anti-IgE were subsequently expressed as ⁇ g/ml mAbl 1 equivalents.
- HBA human basophils
- HBH/HSA human serum albumin
- lOO ⁇ l cell suspension are added to wells of a V-bottom 96-well plate containing lOO ⁇ l diluted test sample or vaccine induced antibody. Each test sample is tested at a range of dilutions with 6 wells for each dilution. Well contents are mixed briefly using a plate shaker, before incubation at 37°C for 30 minutes with shaking at 120 rpm.
- the degree of inhibition of histamine release can be calculated using the formula:
- FIGs 11 to 14 The results of the histamine release activity of the PI 5 disulphide bridge cyclised peptides conjugated to the BSA carriers using the chemistry ofthe present invention are shown in FIGs 11 to 14.
- FIG 11, A and B show the histamine release blocking activity of antiserum induced by PI 5c, P15d and P15e; in comparison with the positive controls: 1079 BSA, PT11 and mAb005, and the negative controls BSA-BAL (activated carrier alone), anti-BSA, non-specific isotype controls (IgGl and IgG2b); also shown are the data produced for spontanteous release of histamine, and histamine release after triggering with allergen, and total histamine content of the cells (released by detergent).
- BSA-BAL activated carrier alone
- anti-BSA anti-BSA
- IgGl and IgG2b non-specific isotype controls
- FIG 12, A and B show the histamine release blocking activity of antiserum induced by PI 5c compared to the same controls as in FIG 11, with the addition of a further positive control 1079 HBC, and one additional negative control HBC wt.
- FIG 13 shows the anaphylactogenicity of the same test samples (antiserum added to HBA in the absence of allergen) as described for FIG 11 (P15c, P15d and P15e).
- FIG 14 shows the anaphylactogenicity ofthe same test samples as described for FIG 12.
- PI 5 c, P15d and P15e induced antisera that inhibited histamine release from human basophils after triggering with allergen, without the antiserum being anaphylactogenic themselves.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0113439-6A BR0113439A (en) | 2000-08-22 | 2001-08-17 | Process for Manufacturing a Vaccine Immunogen Derived from IgE Peptide Maleimide, Use of It, Conjugate Suitable for Use in a Vaccine, and Vaccine Composition |
KR10-2003-7002628A KR20030062405A (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
IL15453201A IL154532A0 (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
PL01365788A PL365788A1 (en) | 2000-08-22 | 2001-08-17 | Novel compounds and process |
AU2002214951A AU2002214951A1 (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
CA002420086A CA2420086A1 (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
MXPA03001631A MXPA03001631A (en) | 2000-08-22 | 2001-08-17 | Novel compounds and process. |
US10/362,527 US20040030106A1 (en) | 2000-08-22 | 2001-08-17 | Novel compounds and process |
EP01983441A EP1311536A2 (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
HU0301725A HUP0301725A3 (en) | 2000-08-22 | 2001-08-17 | Novel compounds and process |
JP2002521504A JP2004514655A (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogen containing disulfide-bridged cyclized peptide and its use in treating allergy |
NO20030822A NO20030822L (en) | 2000-08-22 | 2003-02-21 | New compounds and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0020717.5A GB0020717D0 (en) | 2000-08-22 | 2000-08-22 | Novel compounds and process |
GB0020717.5 | 2000-08-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002016409A2 true WO2002016409A2 (en) | 2002-02-28 |
WO2002016409A3 WO2002016409A3 (en) | 2002-08-29 |
Family
ID=9898110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/009576 WO2002016409A2 (en) | 2000-08-22 | 2001-08-17 | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040030106A1 (en) |
EP (1) | EP1311536A2 (en) |
JP (1) | JP2004514655A (en) |
KR (1) | KR20030062405A (en) |
CN (1) | CN1471539A (en) |
AR (1) | AR030458A1 (en) |
AU (1) | AU2002214951A1 (en) |
BR (1) | BR0113439A (en) |
CA (1) | CA2420086A1 (en) |
GB (1) | GB0020717D0 (en) |
HU (1) | HUP0301725A3 (en) |
IL (1) | IL154532A0 (en) |
MX (1) | MXPA03001631A (en) |
NO (1) | NO20030822L (en) |
PL (1) | PL365788A1 (en) |
WO (1) | WO2002016409A2 (en) |
ZA (1) | ZA200301437B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002034288A2 (en) * | 2000-10-27 | 2002-05-02 | Smithkline Beecham Biologicals S.A. | Vaccine for treating allergy |
WO2003092714A2 (en) * | 2002-04-30 | 2003-11-13 | Glaxosmithkline Biologicals S.A. | Peptide variants of ige constrained by beta-lactam bond |
EP1718669A1 (en) * | 2004-02-02 | 2006-11-08 | Tanox, Inc. | Identification of novel ige epitopes |
US8304382B2 (en) * | 2006-07-21 | 2012-11-06 | Cristalia Productos Quimicos Farmaceuticos Ltda. | Anti-inflammatory and anti-allergic cyclic peptides |
CN101511861B (en) * | 2006-07-21 | 2013-04-24 | 克里斯泰利亚化学药物产品有限公司 | Anti-inflammatory and antiallergic cyclic peptides |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007277556B2 (en) * | 2006-07-26 | 2012-11-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
KR20120116396A (en) * | 2009-11-16 | 2012-10-22 | 에프. 호프만-라 로슈 아게 | Calibration reagent and uses thereof |
EP2458467B1 (en) | 2010-11-26 | 2013-08-28 | ABB Research Ltd. | Method and system for monitoring an industrial system |
CN106366160B (en) * | 2016-10-11 | 2019-06-14 | 厦门大学 | The method that building is rich in disulfide bond peptide molecule skeleton is precisely matched based on disulfide bond |
WO2019194656A1 (en) * | 2018-04-06 | 2019-10-10 | (주)에스엘에스바이오 | Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306943A2 (en) * | 1987-09-10 | 1989-03-15 | Neorx Corporation | Immunconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
EP0467701A2 (en) * | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | Cyclic HIV principal neutralizing determinant peptides |
WO1999067293A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Peptide composition as immunogen for the treatment of allergy |
-
2000
- 2000-08-22 GB GBGB0020717.5A patent/GB0020717D0/en not_active Ceased
-
2001
- 2001-08-17 AU AU2002214951A patent/AU2002214951A1/en not_active Abandoned
- 2001-08-17 MX MXPA03001631A patent/MXPA03001631A/en unknown
- 2001-08-17 HU HU0301725A patent/HUP0301725A3/en unknown
- 2001-08-17 BR BR0113439-6A patent/BR0113439A/en not_active Application Discontinuation
- 2001-08-17 US US10/362,527 patent/US20040030106A1/en not_active Abandoned
- 2001-08-17 JP JP2002521504A patent/JP2004514655A/en active Pending
- 2001-08-17 EP EP01983441A patent/EP1311536A2/en not_active Withdrawn
- 2001-08-17 WO PCT/EP2001/009576 patent/WO2002016409A2/en not_active Application Discontinuation
- 2001-08-17 IL IL15453201A patent/IL154532A0/en unknown
- 2001-08-17 CA CA002420086A patent/CA2420086A1/en not_active Abandoned
- 2001-08-17 CN CNA018177778A patent/CN1471539A/en active Pending
- 2001-08-17 PL PL01365788A patent/PL365788A1/en not_active Application Discontinuation
- 2001-08-17 KR KR10-2003-7002628A patent/KR20030062405A/en not_active Application Discontinuation
- 2001-08-21 AR ARP010103969A patent/AR030458A1/en unknown
-
2003
- 2003-02-21 ZA ZA200301437A patent/ZA200301437B/en unknown
- 2003-02-21 NO NO20030822A patent/NO20030822L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306943A2 (en) * | 1987-09-10 | 1989-03-15 | Neorx Corporation | Immunconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
EP0467701A2 (en) * | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | Cyclic HIV principal neutralizing determinant peptides |
WO1999067293A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Peptide composition as immunogen for the treatment of allergy |
Non-Patent Citations (1)
Title |
---|
BOECKLER C ET AL: "Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 191, no. 1, 10 May 1996 (1996-05-10), pages 1-10, XP004020848 ISSN: 0022-1759 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002034288A2 (en) * | 2000-10-27 | 2002-05-02 | Smithkline Beecham Biologicals S.A. | Vaccine for treating allergy |
WO2002034288A3 (en) * | 2000-10-27 | 2003-03-13 | Smithkline Beecham Biolog | Vaccine for treating allergy |
WO2003092714A2 (en) * | 2002-04-30 | 2003-11-13 | Glaxosmithkline Biologicals S.A. | Peptide variants of ige constrained by beta-lactam bond |
WO2003092714A3 (en) * | 2002-04-30 | 2004-03-18 | Glaxosmithkline Biolog Sa | Peptide variants of ige constrained by beta-lactam bond |
EP1718669A1 (en) * | 2004-02-02 | 2006-11-08 | Tanox, Inc. | Identification of novel ige epitopes |
EP1718669A4 (en) * | 2004-02-02 | 2007-10-10 | Tanox Inc | Identification of novel ige epitopes |
JP2008507474A (en) * | 2004-02-02 | 2008-03-13 | タノックス インコーポレイテッド | Identification of novel IgE epitopes |
AU2004315197B2 (en) * | 2004-02-02 | 2009-06-04 | Tanox, Inc. | Identification of novel IgE epitopes |
US8304382B2 (en) * | 2006-07-21 | 2012-11-06 | Cristalia Productos Quimicos Farmaceuticos Ltda. | Anti-inflammatory and anti-allergic cyclic peptides |
CN101511861B (en) * | 2006-07-21 | 2013-04-24 | 克里斯泰利亚化学药物产品有限公司 | Anti-inflammatory and antiallergic cyclic peptides |
Also Published As
Publication number | Publication date |
---|---|
CA2420086A1 (en) | 2002-02-28 |
PL365788A1 (en) | 2005-01-10 |
JP2004514655A (en) | 2004-05-20 |
AU2002214951A1 (en) | 2002-03-04 |
HUP0301725A3 (en) | 2004-11-29 |
NO20030822D0 (en) | 2003-02-21 |
US20040030106A1 (en) | 2004-02-12 |
NO20030822L (en) | 2003-03-31 |
WO2002016409A3 (en) | 2002-08-29 |
GB0020717D0 (en) | 2000-10-11 |
IL154532A0 (en) | 2003-09-17 |
CN1471539A (en) | 2004-01-28 |
ZA200301437B (en) | 2004-05-21 |
KR20030062405A (en) | 2003-07-25 |
AR030458A1 (en) | 2003-08-20 |
EP1311536A2 (en) | 2003-05-21 |
BR0113439A (en) | 2004-07-06 |
HUP0301725A2 (en) | 2003-08-28 |
MXPA03001631A (en) | 2004-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4087898B2 (en) | Conjugates of antigens with poor immunogenicity and synthetic peptide carriers and vaccines comprising them | |
EP1155038A1 (en) | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses | |
JP2003231696A (en) | Peptide immunogen | |
US20040030106A1 (en) | Novel compounds and process | |
WO2003092714A2 (en) | Peptide variants of ige constrained by beta-lactam bond | |
US20040115220A1 (en) | Vaccine | |
KR20020007313A (en) | Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses | |
JP2000513353A (en) | Vaccines comprising carrier-bound antigens with labile bonds | |
JP2002537354A (en) | Peptides, and H. Immunogen comprising a carrier derived from protein D of H. influenzae | |
Kaushik et al. | Synthesis of peptide based epsilon toxin vaccine by covalent anchoring to tetanus toxoid | |
US20030170229A1 (en) | Vaccine | |
US20030147906A1 (en) | Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of lgE, antagonists thereof, and their therapeutic uses | |
JP2002540217A (en) | Peptide vaccine for dog allergy | |
US20180186896A1 (en) | Vaccines for the treatment and prevention of ige mediated diseases | |
US20050214285A1 (en) | Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses | |
CA2144936A1 (en) | Antibody conjugates with improved properties | |
MXPA00011938A (en) | Peptide composition as immunogen for the treatment of allergy | |
EP0674907A2 (en) | Conjugabes of a antibody and a carrier protein, useful for active immunotherapy | |
NZ286599A (en) | use of protein antibody conjugate for stimulating an immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2420086 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 154532 Country of ref document: IL Ref document number: 2002521504 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-517 Country of ref document: CZ Ref document number: 2003/01437 Country of ref document: ZA Ref document number: PA/a/2003/001631 Country of ref document: MX Ref document number: 200301437 Country of ref document: ZA Ref document number: 524343 Country of ref document: NZ Ref document number: 221/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037002628 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002214951 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 03016546 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001983441 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018177778 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001983441 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-517 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037002628 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10362527 Country of ref document: US |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2003-517 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001983441 Country of ref document: EP |